nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—Gastric ulcer—Alendronate—Paget's disease of bone	0.015	0.0198	CcSEcCtD
Gefitinib—Rectal disorder—Risedronate—Paget's disease of bone	0.0143	0.0189	CcSEcCtD
Gefitinib—Interstitial pneumonia—Pamidronate—Paget's disease of bone	0.0138	0.0182	CcSEcCtD
Gefitinib—Anorectal disorder—Risedronate—Paget's disease of bone	0.0133	0.0176	CcSEcCtD
Gefitinib—Ocular hyperaemia—Zoledronate—Paget's disease of bone	0.013	0.0171	CcSEcCtD
Gefitinib—Gastric ulcer—Risedronate—Paget's disease of bone	0.012	0.0159	CcSEcCtD
Gefitinib—LOC400927-CSNK1E—Circadian rythm related genes—TNFRSF11A—Paget's disease of bone	0.0117	0.0481	CbGpPWpGaD
Gefitinib—IRAK1—p75NTR recruits signalling complexes—SQSTM1—Paget's disease of bone	0.0117	0.0481	CbGpPWpGaD
Gefitinib—IRAK1—NF-kB is activated and signals survival—SQSTM1—Paget's disease of bone	0.0117	0.0481	CbGpPWpGaD
Gefitinib—Hypomagnesaemia—Pamidronate—Paget's disease of bone	0.0105	0.0138	CcSEcCtD
Gefitinib—IRAK1—p75NTR signals via NF-kB—SQSTM1—Paget's disease of bone	0.00994	0.0407	CbGpPWpGaD
Gefitinib—Hypomagnesaemia—Zoledronate—Paget's disease of bone	0.00956	0.0127	CcSEcCtD
Gefitinib—Drug interaction—Alendronate—Paget's disease of bone	0.0094	0.0124	CcSEcCtD
Gefitinib—Interstitial lung disease—Pamidronate—Paget's disease of bone	0.00939	0.0124	CcSEcCtD
Gefitinib—Ulcer—Alendronate—Paget's disease of bone	0.00922	0.0122	CcSEcCtD
Gefitinib—Amblyopia—Risedronate—Paget's disease of bone	0.00906	0.012	CcSEcCtD
Gefitinib—Pleural effusion—Pamidronate—Paget's disease of bone	0.00868	0.0115	CcSEcCtD
Gefitinib—Interstitial lung disease—Zoledronate—Paget's disease of bone	0.00858	0.0114	CcSEcCtD
Gefitinib—Melaena—Alendronate—Paget's disease of bone	0.00852	0.0113	CcSEcCtD
Gefitinib—IRAK4—IL1-mediated signaling events—SQSTM1—Paget's disease of bone	0.00819	0.0335	CbGpPWpGaD
Gefitinib—CSNK1E—Regulation of PLK1 Activity at G2/M Transition—OPTN—Paget's disease of bone	0.00804	0.0329	CbGpPWpGaD
Gefitinib—Pleural effusion—Zoledronate—Paget's disease of bone	0.00793	0.0105	CcSEcCtD
Gefitinib—Ulcer—Risedronate—Paget's disease of bone	0.0074	0.00978	CcSEcCtD
Gefitinib—IRAK4—Interleukin-1 signaling—SQSTM1—Paget's disease of bone	0.00719	0.0295	CbGpPWpGaD
Gefitinib—Proteinuria—Zoledronate—Paget's disease of bone	0.00691	0.00915	CcSEcCtD
Gefitinib—Cystitis noninfective—Risedronate—Paget's disease of bone	0.00683	0.00904	CcSEcCtD
Gefitinib—Protein urine present—Zoledronate—Paget's disease of bone	0.00682	0.00902	CcSEcCtD
Gefitinib—Cystitis—Risedronate—Paget's disease of bone	0.00675	0.00894	CcSEcCtD
Gefitinib—CHEK2—DNA Damage Response—PML—Paget's disease of bone	0.00664	0.0272	CbGpPWpGaD
Gefitinib—Pain—Tiludronate—Paget's disease of bone	0.00652	0.00862	CcSEcCtD
Gefitinib—Dry eye—Risedronate—Paget's disease of bone	0.00646	0.00855	CcSEcCtD
Gefitinib—CHEK2—miRNA Regulation of DNA Damage Response—PML—Paget's disease of bone	0.00642	0.0263	CbGpPWpGaD
Gefitinib—Bladder pain—Risedronate—Paget's disease of bone	0.00632	0.00837	CcSEcCtD
Gefitinib—Gastrointestinal pain—Tiludronate—Paget's disease of bone	0.00623	0.00825	CcSEcCtD
Gefitinib—CSNK1E—Circadian rythm related genes—TNFRSF11A—Paget's disease of bone	0.00617	0.0252	CbGpPWpGaD
Gefitinib—IRAK4—AGE/RAGE pathway—ALPL—Paget's disease of bone	0.00605	0.0248	CbGpPWpGaD
Gefitinib—CSNK1E—G2/M Transition—OPTN—Paget's disease of bone	0.00604	0.0247	CbGpPWpGaD
Gefitinib—Abdominal pain—Tiludronate—Paget's disease of bone	0.00603	0.00797	CcSEcCtD
Gefitinib—CSNK1E—Mitotic G2-G2/M phases—OPTN—Paget's disease of bone	0.00595	0.0244	CbGpPWpGaD
Gefitinib—Dry skin—Alendronate—Paget's disease of bone	0.0058	0.00767	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Alendronate—Paget's disease of bone	0.0057	0.00754	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Etidronic acid—Paget's disease of bone	0.00567	0.00751	CcSEcCtD
Gefitinib—Thrombophlebitis—Pamidronate—Paget's disease of bone	0.00558	0.00738	CcSEcCtD
Gefitinib—IRAK4—IL-1 signaling pathway—SQSTM1—Paget's disease of bone	0.00558	0.0228	CbGpPWpGaD
Gefitinib—Asthenia—Tiludronate—Paget's disease of bone	0.00547	0.00724	CcSEcCtD
Gefitinib—IRAK1—IL1-mediated signaling events—SQSTM1—Paget's disease of bone	0.00544	0.0223	CbGpPWpGaD
Gefitinib—Diarrhoea—Tiludronate—Paget's disease of bone	0.00521	0.0069	CcSEcCtD
Gefitinib—Atrial fibrillation—Pamidronate—Paget's disease of bone	0.00509	0.00674	CcSEcCtD
Gefitinib—Eye pain—Zoledronate—Paget's disease of bone	0.00488	0.00646	CcSEcCtD
Gefitinib—Erythema multiforme—Etidronic acid—Paget's disease of bone	0.00486	0.00643	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Alendronate—Paget's disease of bone	0.00483	0.0064	CcSEcCtD
Gefitinib—IRAK1—Interleukin-1 signaling—SQSTM1—Paget's disease of bone	0.00477	0.0196	CbGpPWpGaD
Gefitinib—Stomatitis—Alendronate—Paget's disease of bone	0.00475	0.00629	CcSEcCtD
Gefitinib—EGFR—Signaling events mediated by TCPTP—CSF1—Paget's disease of bone	0.0047	0.0192	CbGpPWpGaD
Gefitinib—Atrial fibrillation—Zoledronate—Paget's disease of bone	0.00465	0.00616	CcSEcCtD
Gefitinib—ERBB3—Apoptosis-related network due to altered Notch3 in ovarian cancer—SQSTM1—Paget's disease of bone	0.00458	0.0188	CbGpPWpGaD
Gefitinib—LOC400927-CSNK1E—Circadian rythm related genes—PML—Paget's disease of bone	0.00455	0.0186	CbGpPWpGaD
Gefitinib—Alopecia—Etidronic acid—Paget's disease of bone	0.00454	0.00601	CcSEcCtD
Gefitinib—Nausea—Tiludronate—Paget's disease of bone	0.00453	0.00599	CcSEcCtD
Gefitinib—Haemoglobin—Alendronate—Paget's disease of bone	0.0044	0.00582	CcSEcCtD
Gefitinib—Hypokalaemia—Pamidronate—Paget's disease of bone	0.00439	0.00581	CcSEcCtD
Gefitinib—Haemorrhage—Alendronate—Paget's disease of bone	0.00438	0.00579	CcSEcCtD
Gefitinib—Oedema peripheral—Alendronate—Paget's disease of bone	0.00431	0.00571	CcSEcCtD
Gefitinib—Erythema multiforme—Alendronate—Paget's disease of bone	0.00414	0.00548	CcSEcCtD
Gefitinib—Anaemia—Etidronic acid—Paget's disease of bone	0.00413	0.00547	CcSEcCtD
Gefitinib—Dehydration—Zoledronate—Paget's disease of bone	0.0041	0.00543	CcSEcCtD
Gefitinib—Angioedema—Etidronic acid—Paget's disease of bone	0.00409	0.00541	CcSEcCtD
Gefitinib—Hypokalaemia—Zoledronate—Paget's disease of bone	0.00401	0.00531	CcSEcCtD
Gefitinib—Pneumonia—Risedronate—Paget's disease of bone	0.00394	0.00521	CcSEcCtD
Gefitinib—Infestation NOS—Risedronate—Paget's disease of bone	0.00391	0.00518	CcSEcCtD
Gefitinib—Infestation—Risedronate—Paget's disease of bone	0.00391	0.00518	CcSEcCtD
Gefitinib—Alopecia—Alendronate—Paget's disease of bone	0.00387	0.00512	CcSEcCtD
Gefitinib—EGFR—Signaling events mediated by PTP1B—CSF1—Paget's disease of bone	0.00381	0.0156	CbGpPWpGaD
Gefitinib—Conjunctivitis—Risedronate—Paget's disease of bone	0.0038	0.00503	CcSEcCtD
Gefitinib—Pneumonia—Pamidronate—Paget's disease of bone	0.00374	0.00495	CcSEcCtD
Gefitinib—Infestation—Pamidronate—Paget's disease of bone	0.00372	0.00492	CcSEcCtD
Gefitinib—Infestation NOS—Pamidronate—Paget's disease of bone	0.00372	0.00492	CcSEcCtD
Gefitinib—IRAK1—IL-1 signaling pathway—SQSTM1—Paget's disease of bone	0.0037	0.0152	CbGpPWpGaD
Gefitinib—Hepatobiliary disease—Risedronate—Paget's disease of bone	0.0037	0.0049	CcSEcCtD
Gefitinib—Infection—Etidronic acid—Paget's disease of bone	0.00363	0.0048	CcSEcCtD
Gefitinib—Stomatitis—Pamidronate—Paget's disease of bone	0.00363	0.0048	CcSEcCtD
Gefitinib—IRAK4—Signaling by Interleukins—INPP5D—Paget's disease of bone	0.00363	0.0148	CbGpPWpGaD
Gefitinib—Conjunctivitis—Pamidronate—Paget's disease of bone	0.00362	0.00478	CcSEcCtD
Gefitinib—Haematuria—Pamidronate—Paget's disease of bone	0.00355	0.00469	CcSEcCtD
Gefitinib—Haemoglobin—Risedronate—Paget's disease of bone	0.00353	0.00467	CcSEcCtD
Gefitinib—Anaemia—Alendronate—Paget's disease of bone	0.00352	0.00466	CcSEcCtD
Gefitinib—Haemorrhage—Risedronate—Paget's disease of bone	0.00351	0.00465	CcSEcCtD
Gefitinib—CHEK2—Integrated Breast Cancer Pathway—PML—Paget's disease of bone	0.00351	0.0144	CbGpPWpGaD
Gefitinib—Angioedema—Alendronate—Paget's disease of bone	0.00348	0.00461	CcSEcCtD
Gefitinib—Urinary tract disorder—Risedronate—Paget's disease of bone	0.00347	0.00459	CcSEcCtD
Gefitinib—Oedema peripheral—Risedronate—Paget's disease of bone	0.00346	0.00458	CcSEcCtD
Gefitinib—Weight decreased—Zoledronate—Paget's disease of bone	0.00345	0.00456	CcSEcCtD
Gefitinib—Urethral disorder—Risedronate—Paget's disease of bone	0.00344	0.00456	CcSEcCtD
Gefitinib—Malaise—Alendronate—Paget's disease of bone	0.00344	0.00455	CcSEcCtD
Gefitinib—Infestation NOS—Zoledronate—Paget's disease of bone	0.0034	0.0045	CcSEcCtD
Gefitinib—Infestation—Zoledronate—Paget's disease of bone	0.0034	0.0045	CcSEcCtD
Gefitinib—Haemoglobin—Pamidronate—Paget's disease of bone	0.00336	0.00444	CcSEcCtD
Gefitinib—Haemorrhage—Pamidronate—Paget's disease of bone	0.00334	0.00442	CcSEcCtD
Gefitinib—Stomatitis—Zoledronate—Paget's disease of bone	0.00331	0.00438	CcSEcCtD
Gefitinib—Conjunctivitis—Zoledronate—Paget's disease of bone	0.0033	0.00437	CcSEcCtD
Gefitinib—Urinary tract disorder—Pamidronate—Paget's disease of bone	0.0033	0.00436	CcSEcCtD
Gefitinib—Eye disorder—Risedronate—Paget's disease of bone	0.00328	0.00434	CcSEcCtD
Gefitinib—Urethral disorder—Pamidronate—Paget's disease of bone	0.00327	0.00433	CcSEcCtD
Gefitinib—Cardiac disorder—Risedronate—Paget's disease of bone	0.00326	0.00431	CcSEcCtD
Gefitinib—IRAK4—Signaling by Interleukins—SQSTM1—Paget's disease of bone	0.00325	0.0133	CbGpPWpGaD
Gefitinib—Haematuria—Zoledronate—Paget's disease of bone	0.00324	0.00429	CcSEcCtD
Gefitinib—IRAK1—Apoptosis Modulation and Signaling—TNFRSF11B—Paget's disease of bone	0.00321	0.0131	CbGpPWpGaD
Gefitinib—Angiopathy—Risedronate—Paget's disease of bone	0.00319	0.00422	CcSEcCtD
Gefitinib—Mediastinal disorder—Risedronate—Paget's disease of bone	0.00317	0.00419	CcSEcCtD
Gefitinib—Arrhythmia—Risedronate—Paget's disease of bone	0.00314	0.00415	CcSEcCtD
Gefitinib—Constipation—Etidronic acid—Paget's disease of bone	0.00312	0.00413	CcSEcCtD
Gefitinib—Eye disorder—Pamidronate—Paget's disease of bone	0.00312	0.00413	CcSEcCtD
Gefitinib—Cardiac disorder—Pamidronate—Paget's disease of bone	0.0031	0.0041	CcSEcCtD
Gefitinib—Infection—Alendronate—Paget's disease of bone	0.00309	0.00409	CcSEcCtD
Gefitinib—IRAK1—p75(NTR)-mediated signaling—SQSTM1—Paget's disease of bone	0.00309	0.0126	CbGpPWpGaD
Gefitinib—Malnutrition—Risedronate—Paget's disease of bone	0.00306	0.00405	CcSEcCtD
Gefitinib—Angiopathy—Pamidronate—Paget's disease of bone	0.00303	0.00401	CcSEcCtD
Gefitinib—Urinary tract disorder—Zoledronate—Paget's disease of bone	0.00301	0.00399	CcSEcCtD
Gefitinib—Mediastinal disorder—Pamidronate—Paget's disease of bone	0.00301	0.00398	CcSEcCtD
Gefitinib—Oedema peripheral—Zoledronate—Paget's disease of bone	0.003	0.00398	CcSEcCtD
Gefitinib—Urethral disorder—Zoledronate—Paget's disease of bone	0.00299	0.00396	CcSEcCtD
Gefitinib—Gastrointestinal pain—Etidronic acid—Paget's disease of bone	0.00298	0.00395	CcSEcCtD
Gefitinib—Alopecia—Pamidronate—Paget's disease of bone	0.00295	0.0039	CcSEcCtD
Gefitinib—CHEK2—Integrated Pancreatic Cancer Pathway—PML—Paget's disease of bone	0.00291	0.0119	CbGpPWpGaD
Gefitinib—Malnutrition—Pamidronate—Paget's disease of bone	0.00291	0.00385	CcSEcCtD
Gefitinib—Urticaria—Etidronic acid—Paget's disease of bone	0.0029	0.00384	CcSEcCtD
Gefitinib—Abdominal pain—Etidronic acid—Paget's disease of bone	0.00289	0.00382	CcSEcCtD
Gefitinib—Eye disorder—Zoledronate—Paget's disease of bone	0.00285	0.00377	CcSEcCtD
Gefitinib—Cardiac disorder—Zoledronate—Paget's disease of bone	0.00283	0.00375	CcSEcCtD
Gefitinib—Anaemia—Risedronate—Paget's disease of bone	0.00283	0.00374	CcSEcCtD
Gefitinib—Angioedema—Risedronate—Paget's disease of bone	0.00279	0.0037	CcSEcCtD
Gefitinib—Angiopathy—Zoledronate—Paget's disease of bone	0.00277	0.00366	CcSEcCtD
Gefitinib—Mediastinal disorder—Zoledronate—Paget's disease of bone	0.00275	0.00364	CcSEcCtD
Gefitinib—Arrhythmia—Zoledronate—Paget's disease of bone	0.00272	0.00361	CcSEcCtD
Gefitinib—Alopecia—Zoledronate—Paget's disease of bone	0.0027	0.00357	CcSEcCtD
Gefitinib—Hypersensitivity—Etidronic acid—Paget's disease of bone	0.00269	0.00356	CcSEcCtD
Gefitinib—IRAK1—p75 NTR receptor-mediated signalling—SQSTM1—Paget's disease of bone	0.00269	0.011	CbGpPWpGaD
Gefitinib—EGFR—AGE/RAGE pathway—ALPL—Paget's disease of bone	0.00269	0.011	CbGpPWpGaD
Gefitinib—Anaemia—Pamidronate—Paget's disease of bone	0.00269	0.00355	CcSEcCtD
Gefitinib—MAP2K5—BDNF signaling pathway—ALPL—Paget's disease of bone	0.00268	0.011	CbGpPWpGaD
Gefitinib—Cough—Risedronate—Paget's disease of bone	0.00267	0.00353	CcSEcCtD
Gefitinib—Constipation—Alendronate—Paget's disease of bone	0.00266	0.00352	CcSEcCtD
Gefitinib—Pain—Alendronate—Paget's disease of bone	0.00266	0.00352	CcSEcCtD
Gefitinib—Angioedema—Pamidronate—Paget's disease of bone	0.00266	0.00351	CcSEcCtD
Gefitinib—IRAK4—Regulation of toll-like receptor signaling pathway—SQSTM1—Paget's disease of bone	0.00266	0.0109	CbGpPWpGaD
Gefitinib—Malnutrition—Zoledronate—Paget's disease of bone	0.00266	0.00351	CcSEcCtD
Gefitinib—Malaise—Pamidronate—Paget's disease of bone	0.00262	0.00347	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Risedronate—Paget's disease of bone	0.00259	0.00342	CcSEcCtD
Gefitinib—Pruritus—Etidronic acid—Paget's disease of bone	0.00258	0.00342	CcSEcCtD
Gefitinib—Dry mouth—Risedronate—Paget's disease of bone	0.00255	0.00337	CcSEcCtD
Gefitinib—Gastrointestinal pain—Alendronate—Paget's disease of bone	0.00254	0.00337	CcSEcCtD
Gefitinib—Cough—Pamidronate—Paget's disease of bone	0.00254	0.00336	CcSEcCtD
Gefitinib—Diarrhoea—Etidronic acid—Paget's disease of bone	0.0025	0.0033	CcSEcCtD
Gefitinib—Infection—Risedronate—Paget's disease of bone	0.00248	0.00328	CcSEcCtD
Gefitinib—Urticaria—Alendronate—Paget's disease of bone	0.00247	0.00327	CcSEcCtD
Gefitinib—Body temperature increased—Alendronate—Paget's disease of bone	0.00246	0.00325	CcSEcCtD
Gefitinib—Abdominal pain—Alendronate—Paget's disease of bone	0.00246	0.00325	CcSEcCtD
Gefitinib—Shock—Risedronate—Paget's disease of bone	0.00246	0.00325	CcSEcCtD
Gefitinib—Anaemia—Zoledronate—Paget's disease of bone	0.00245	0.00325	CcSEcCtD
Gefitinib—Nervous system disorder—Risedronate—Paget's disease of bone	0.00245	0.00324	CcSEcCtD
Gefitinib—Angioedema—Zoledronate—Paget's disease of bone	0.00243	0.00321	CcSEcCtD
Gefitinib—Skin disorder—Risedronate—Paget's disease of bone	0.00242	0.00321	CcSEcCtD
Gefitinib—IRAK1—Signaling by Interleukins—INPP5D—Paget's disease of bone	0.00241	0.00985	CbGpPWpGaD
Gefitinib—Malaise—Zoledronate—Paget's disease of bone	0.00239	0.00317	CcSEcCtD
Gefitinib—CSNK1E—Circadian rythm related genes—PML—Paget's disease of bone	0.00239	0.0098	CbGpPWpGaD
Gefitinib—Infection—Pamidronate—Paget's disease of bone	0.00236	0.00312	CcSEcCtD
Gefitinib—Shock—Pamidronate—Paget's disease of bone	0.00233	0.00309	CcSEcCtD
Gefitinib—Nervous system disorder—Pamidronate—Paget's disease of bone	0.00233	0.00308	CcSEcCtD
Gefitinib—Thrombocytopenia—Pamidronate—Paget's disease of bone	0.00232	0.00307	CcSEcCtD
Gefitinib—Vomiting—Etidronic acid—Paget's disease of bone	0.00232	0.00307	CcSEcCtD
Gefitinib—Cough—Zoledronate—Paget's disease of bone	0.00232	0.00307	CcSEcCtD
Gefitinib—Rash—Etidronic acid—Paget's disease of bone	0.0023	0.00305	CcSEcCtD
Gefitinib—Dermatitis—Etidronic acid—Paget's disease of bone	0.0023	0.00304	CcSEcCtD
Gefitinib—Hypersensitivity—Alendronate—Paget's disease of bone	0.00229	0.00303	CcSEcCtD
Gefitinib—Anorexia—Pamidronate—Paget's disease of bone	0.00226	0.00299	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—Paget's disease of bone	0.00224	0.00297	CcSEcCtD
Gefitinib—Asthenia—Alendronate—Paget's disease of bone	0.00223	0.00295	CcSEcCtD
Gefitinib—Dyspnoea—Risedronate—Paget's disease of bone	0.00222	0.00294	CcSEcCtD
Gefitinib—Hypotension—Pamidronate—Paget's disease of bone	0.00222	0.00293	CcSEcCtD
Gefitinib—Dry mouth—Zoledronate—Paget's disease of bone	0.00221	0.00293	CcSEcCtD
Gefitinib—Pruritus—Alendronate—Paget's disease of bone	0.0022	0.00291	CcSEcCtD
Gefitinib—Nausea—Etidronic acid—Paget's disease of bone	0.00217	0.00287	CcSEcCtD
Gefitinib—MAP2K5—EGF/EGFR Signaling Pathway—INPP5D—Paget's disease of bone	0.00217	0.00888	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by Interleukins—SQSTM1—Paget's disease of bone	0.00216	0.00883	CbGpPWpGaD
Gefitinib—Gastrointestinal disorder—Risedronate—Paget's disease of bone	0.00215	0.00285	CcSEcCtD
Gefitinib—Infection—Zoledronate—Paget's disease of bone	0.00215	0.00285	CcSEcCtD
Gefitinib—Fatigue—Risedronate—Paget's disease of bone	0.00215	0.00285	CcSEcCtD
Gefitinib—MAP2K5—BDNF signaling pathway—SQSTM1—Paget's disease of bone	0.00214	0.00874	CbGpPWpGaD
Gefitinib—Pain—Risedronate—Paget's disease of bone	0.00213	0.00282	CcSEcCtD
Gefitinib—Constipation—Risedronate—Paget's disease of bone	0.00213	0.00282	CcSEcCtD
Gefitinib—Shock—Zoledronate—Paget's disease of bone	0.00213	0.00282	CcSEcCtD
Gefitinib—Diarrhoea—Alendronate—Paget's disease of bone	0.00213	0.00282	CcSEcCtD
Gefitinib—Nervous system disorder—Zoledronate—Paget's disease of bone	0.00213	0.00281	CcSEcCtD
Gefitinib—Thrombocytopenia—Zoledronate—Paget's disease of bone	0.00212	0.00281	CcSEcCtD
Gefitinib—Dyspnoea—Pamidronate—Paget's disease of bone	0.00212	0.0028	CcSEcCtD
Gefitinib—Skin disorder—Zoledronate—Paget's disease of bone	0.0021	0.00278	CcSEcCtD
Gefitinib—Anorexia—Zoledronate—Paget's disease of bone	0.00207	0.00273	CcSEcCtD
Gefitinib—Decreased appetite—Pamidronate—Paget's disease of bone	0.00206	0.00273	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Pamidronate—Paget's disease of bone	0.00205	0.00271	CcSEcCtD
Gefitinib—Fatigue—Pamidronate—Paget's disease of bone	0.00205	0.00271	CcSEcCtD
Gefitinib—Gastrointestinal pain—Risedronate—Paget's disease of bone	0.00204	0.0027	CcSEcCtD
Gefitinib—Pain—Pamidronate—Paget's disease of bone	0.00203	0.00268	CcSEcCtD
Gefitinib—Constipation—Pamidronate—Paget's disease of bone	0.00203	0.00268	CcSEcCtD
Gefitinib—Hypotension—Zoledronate—Paget's disease of bone	0.00202	0.00268	CcSEcCtD
Gefitinib—CHEK2—Cell Cycle—OPTN—Paget's disease of bone	0.002	0.00821	CbGpPWpGaD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—NUP205—Paget's disease of bone	0.00198	0.00812	CbGpPWpGaD
Gefitinib—Urticaria—Risedronate—Paget's disease of bone	0.00198	0.00262	CcSEcCtD
Gefitinib—Vomiting—Alendronate—Paget's disease of bone	0.00198	0.00262	CcSEcCtD
Gefitinib—Abdominal pain—Risedronate—Paget's disease of bone	0.00197	0.00261	CcSEcCtD
Gefitinib—Body temperature increased—Risedronate—Paget's disease of bone	0.00197	0.00261	CcSEcCtD
Gefitinib—Rash—Alendronate—Paget's disease of bone	0.00196	0.00259	CcSEcCtD
Gefitinib—Dermatitis—Alendronate—Paget's disease of bone	0.00196	0.00259	CcSEcCtD
Gefitinib—Gastrointestinal pain—Pamidronate—Paget's disease of bone	0.00194	0.00257	CcSEcCtD
Gefitinib—Dyspnoea—Zoledronate—Paget's disease of bone	0.00193	0.00256	CcSEcCtD
Gefitinib—CSNK1E—Cell Cycle, Mitotic—OPTN—Paget's disease of bone	0.00192	0.00787	CbGpPWpGaD
Gefitinib—Decreased appetite—Zoledronate—Paget's disease of bone	0.00188	0.00249	CcSEcCtD
Gefitinib—Abdominal pain—Pamidronate—Paget's disease of bone	0.00188	0.00248	CcSEcCtD
Gefitinib—Body temperature increased—Pamidronate—Paget's disease of bone	0.00188	0.00248	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Zoledronate—Paget's disease of bone	0.00187	0.00248	CcSEcCtD
Gefitinib—Fatigue—Zoledronate—Paget's disease of bone	0.00187	0.00247	CcSEcCtD
Gefitinib—Pain—Zoledronate—Paget's disease of bone	0.00185	0.00245	CcSEcCtD
Gefitinib—Constipation—Zoledronate—Paget's disease of bone	0.00185	0.00245	CcSEcCtD
Gefitinib—Nausea—Alendronate—Paget's disease of bone	0.00185	0.00244	CcSEcCtD
Gefitinib—Hypersensitivity—Risedronate—Paget's disease of bone	0.00184	0.00243	CcSEcCtD
Gefitinib—ALB—Folate Metabolism—CSF1—Paget's disease of bone	0.00181	0.00743	CbGpPWpGaD
Gefitinib—Asthenia—Risedronate—Paget's disease of bone	0.00179	0.00237	CcSEcCtD
Gefitinib—Gastrointestinal pain—Zoledronate—Paget's disease of bone	0.00177	0.00234	CcSEcCtD
Gefitinib—Pruritus—Risedronate—Paget's disease of bone	0.00177	0.00234	CcSEcCtD
Gefitinib—IRAK1—Regulation of toll-like receptor signaling pathway—SQSTM1—Paget's disease of bone	0.00176	0.00722	CbGpPWpGaD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—PML—Paget's disease of bone	0.00175	0.00718	CbGpPWpGaD
Gefitinib—Hypersensitivity—Pamidronate—Paget's disease of bone	0.00175	0.00231	CcSEcCtD
Gefitinib—Urticaria—Zoledronate—Paget's disease of bone	0.00172	0.00228	CcSEcCtD
Gefitinib—CSNK1E—Cell Cycle—OPTN—Paget's disease of bone	0.00172	0.00703	CbGpPWpGaD
Gefitinib—Abdominal pain—Zoledronate—Paget's disease of bone	0.00171	0.00227	CcSEcCtD
Gefitinib—Body temperature increased—Zoledronate—Paget's disease of bone	0.00171	0.00227	CcSEcCtD
Gefitinib—Diarrhoea—Risedronate—Paget's disease of bone	0.00171	0.00226	CcSEcCtD
Gefitinib—Asthenia—Pamidronate—Paget's disease of bone	0.0017	0.00225	CcSEcCtD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—INPP5D—Paget's disease of bone	0.00169	0.00693	CbGpPWpGaD
Gefitinib—Pruritus—Pamidronate—Paget's disease of bone	0.00168	0.00222	CcSEcCtD
Gefitinib—Diarrhoea—Pamidronate—Paget's disease of bone	0.00162	0.00215	CcSEcCtD
Gefitinib—Hypersensitivity—Zoledronate—Paget's disease of bone	0.0016	0.00211	CcSEcCtD
Gefitinib—Vomiting—Risedronate—Paget's disease of bone	0.00159	0.0021	CcSEcCtD
Gefitinib—Rash—Risedronate—Paget's disease of bone	0.00157	0.00208	CcSEcCtD
Gefitinib—Dermatitis—Risedronate—Paget's disease of bone	0.00157	0.00208	CcSEcCtD
Gefitinib—Asthenia—Zoledronate—Paget's disease of bone	0.00155	0.00206	CcSEcCtD
Gefitinib—Pruritus—Zoledronate—Paget's disease of bone	0.00153	0.00203	CcSEcCtD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—SQSTM1—Paget's disease of bone	0.00152	0.00621	CbGpPWpGaD
Gefitinib—Vomiting—Pamidronate—Paget's disease of bone	0.00151	0.002	CcSEcCtD
Gefitinib—Rash—Pamidronate—Paget's disease of bone	0.0015	0.00198	CcSEcCtD
Gefitinib—Dermatitis—Pamidronate—Paget's disease of bone	0.00149	0.00198	CcSEcCtD
Gefitinib—Diarrhoea—Zoledronate—Paget's disease of bone	0.00148	0.00196	CcSEcCtD
Gefitinib—Nausea—Risedronate—Paget's disease of bone	0.00148	0.00196	CcSEcCtD
Gefitinib—CHEK2—Cell Cycle—NUP205—Paget's disease of bone	0.00142	0.00583	CbGpPWpGaD
Gefitinib—Nausea—Pamidronate—Paget's disease of bone	0.00141	0.00186	CcSEcCtD
Gefitinib—Vomiting—Zoledronate—Paget's disease of bone	0.00138	0.00182	CcSEcCtD
Gefitinib—Rash—Zoledronate—Paget's disease of bone	0.00137	0.00181	CcSEcCtD
Gefitinib—Dermatitis—Zoledronate—Paget's disease of bone	0.00137	0.00181	CcSEcCtD
Gefitinib—CSNK1E—Cell Cycle, Mitotic—NUP205—Paget's disease of bone	0.00136	0.00559	CbGpPWpGaD
Gefitinib—EGFR—Direct p53 effectors—PML—Paget's disease of bone	0.00136	0.00555	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—NUP205—Paget's disease of bone	0.00132	0.00539	CbGpPWpGaD
Gefitinib—Nausea—Zoledronate—Paget's disease of bone	0.00129	0.0017	CcSEcCtD
Gefitinib—EGFR—Integrated Breast Cancer Pathway—PML—Paget's disease of bone	0.00128	0.00522	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling by NGF—SQSTM1—Paget's disease of bone	0.00123	0.00505	CbGpPWpGaD
Gefitinib—CSNK1E—Cell Cycle—NUP205—Paget's disease of bone	0.00122	0.005	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by NGF—SQSTM1—Paget's disease of bone	0.00119	0.00487	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—PML—Paget's disease of bone	0.00116	0.00477	CbGpPWpGaD
Gefitinib—EGFR—EGF/EGFR Signaling Pathway—INPP5D—Paget's disease of bone	0.00116	0.00476	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—INPP5D—Paget's disease of bone	0.00112	0.0046	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—PML—Paget's disease of bone	0.00106	0.00433	CbGpPWpGaD
Gefitinib—MKNK1—Disease—VCP—Paget's disease of bone	0.00105	0.00431	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—SQSTM1—Paget's disease of bone	0.00101	0.00412	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by NGF—SQSTM1—Paget's disease of bone	0.00099	0.00405	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—VCP—Paget's disease of bone	0.000819	0.00335	CbGpPWpGaD
Gefitinib—MKNK1—Disease—NUP205—Paget's disease of bone	0.000805	0.0033	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—VCP—Paget's disease of bone	0.000738	0.00302	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—INPP5D—Paget's disease of bone	0.000726	0.00297	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—SQSTM1—Paget's disease of bone	0.000662	0.00271	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—NUP205—Paget's disease of bone	0.000648	0.00265	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—NUP205—Paget's disease of bone	0.000626	0.00256	CbGpPWpGaD
Gefitinib—ERBB3—Disease—VCP—Paget's disease of bone	0.000624	0.00256	CbGpPWpGaD
Gefitinib—MKNK1—Disease—CALCA—Paget's disease of bone	0.000598	0.00245	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—VCP—Paget's disease of bone	0.000574	0.00235	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—PML—Paget's disease of bone	0.000573	0.00235	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—INPP5D—Paget's disease of bone	0.000553	0.00226	CbGpPWpGaD
Gefitinib—ALB—SLC-mediated transmembrane transport—NUP205—Paget's disease of bone	0.000538	0.0022	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—PML—Paget's disease of bone	0.000533	0.00218	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—NUP205—Paget's disease of bone	0.000517	0.00212	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—SQSTM1—Paget's disease of bone	0.000495	0.00203	CbGpPWpGaD
Gefitinib—ERBB3—Disease—NUP205—Paget's disease of bone	0.000477	0.00195	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—CALCA—Paget's disease of bone	0.000465	0.0019	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—PML—Paget's disease of bone	0.000457	0.00187	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—VCP—Paget's disease of bone	0.000453	0.00186	CbGpPWpGaD
Gefitinib—ABCG2—Transmembrane transport of small molecules—NUP205—Paget's disease of bone	0.000443	0.00182	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—INPP5D—Paget's disease of bone	0.000441	0.0018	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—VCP—Paget's disease of bone	0.000437	0.00179	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—SQSTM1—Paget's disease of bone	0.000431	0.00176	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—NUP205—Paget's disease of bone	0.00043	0.00176	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CALCA—Paget's disease of bone	0.000418	0.00171	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—INPP5D—Paget's disease of bone	0.000404	0.00166	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—SQSTM1—Paget's disease of bone	0.000395	0.00162	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—PML—Paget's disease of bone	0.00038	0.00156	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—INPP5D—Paget's disease of bone	0.000367	0.0015	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—VCP—Paget's disease of bone	0.000364	0.00149	CbGpPWpGaD
Gefitinib—ERBB3—Disease—CALCA—Paget's disease of bone	0.000354	0.00145	CbGpPWpGaD
Gefitinib—EGFR—Disease—VCP—Paget's disease of bone	0.000347	0.00142	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—SQSTM1—Paget's disease of bone	0.000335	0.00137	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—SQSTM1—Paget's disease of bone	0.000329	0.00135	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CALCA—Paget's disease of bone	0.000325	0.00133	CbGpPWpGaD
Gefitinib—EGFR—Immune System—NUP205—Paget's disease of bone	0.000288	0.00118	CbGpPWpGaD
Gefitinib—ALB—Transmembrane transport of small molecules—NUP205—Paget's disease of bone	0.000274	0.00112	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—INPP5D—Paget's disease of bone	0.000269	0.0011	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—INPP5D—Paget's disease of bone	0.000269	0.0011	CbGpPWpGaD
Gefitinib—EGFR—Disease—NUP205—Paget's disease of bone	0.000266	0.00109	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—SQSTM1—Paget's disease of bone	0.000265	0.00108	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CALCA—Paget's disease of bone	0.000257	0.00105	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—SQSTM1—Paget's disease of bone	0.000255	0.00105	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PML—Paget's disease of bone	0.000254	0.00104	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CALCA—Paget's disease of bone	0.000248	0.00102	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—INPP5D—Paget's disease of bone	0.000245	0.001	CbGpPWpGaD
Gefitinib—EGFR—Immune System—INPP5D—Paget's disease of bone	0.000245	0.001	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VCP—Paget's disease of bone	0.000243	0.000996	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—NUP205—Paget's disease of bone	0.00024	0.000981	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CALCA—Paget's disease of bone	0.000234	0.000957	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—INPP5D—Paget's disease of bone	0.00022	0.000902	CbGpPWpGaD
Gefitinib—EGFR—Immune System—SQSTM1—Paget's disease of bone	0.00022	0.0009	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—SQSTM1—Paget's disease of bone	0.000213	0.00087	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—NUP205—Paget's disease of bone	0.000208	0.00085	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CALCA—Paget's disease of bone	0.000206	0.000845	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—INPP5D—Paget's disease of bone	0.000201	0.000822	CbGpPWpGaD
Gefitinib—EGFR—Disease—CALCA—Paget's disease of bone	0.000197	0.000807	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—INPP5D—Paget's disease of bone	0.000177	0.000725	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—NUP205—Paget's disease of bone	0.000149	0.000609	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SQSTM1—Paget's disease of bone	0.000142	0.000582	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—NUP205—Paget's disease of bone	0.000141	0.000575	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CALCA—Paget's disease of bone	0.000138	0.000565	CbGpPWpGaD
Gefitinib—ALB—Metabolism—NUP205—Paget's disease of bone	0.000128	0.000525	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—INPP5D—Paget's disease of bone	0.000127	0.000519	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—INPP5D—Paget's disease of bone	0.00012	0.000491	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—NUP205—Paget's disease of bone	0.000115	0.000471	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—NUP205—Paget's disease of bone	0.000112	0.00046	CbGpPWpGaD
Gefitinib—ALB—Metabolism—INPP5D—Paget's disease of bone	0.000109	0.000447	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—NUP205—Paget's disease of bone	0.000106	0.000433	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—NUP205—Paget's disease of bone	0.000105	0.000429	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—INPP5D—Paget's disease of bone	9.81e-05	0.000402	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—INPP5D—Paget's disease of bone	9.57e-05	0.000392	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—INPP5D—Paget's disease of bone	9.02e-05	0.000369	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—INPP5D—Paget's disease of bone	8.94e-05	0.000366	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NUP205—Paget's disease of bone	6.92e-05	0.000283	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—INPP5D—Paget's disease of bone	5.9e-05	0.000241	CbGpPWpGaD
